Crizotinib is a type Ia tyrosine kinase inhibitor that is approved for the treatment of ALK or ROS1-rearranged advanced non-small cell lung cancers (Goździk-Spychalska et al., 2014). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.